Document is current
Any future updates will be listed below
-
Authors
Jirovec, Elise
Quixabeira, Dafne C. A.
Clubb, James H. A.
Pakola, Santeri A.
Kudling, Tatiana
Arias, Victor
Haybout, Lyna
Jalkanen, Katriina
Alanko, Tuomo
Monberg, Tine
Khammari, Amir
Dreno, Brigitte
Svane, Inge Marie
Block, Matthew S.
Adamo, Daniel A.
Mäenpää, Johanna
Kistler, Claudia
Sorsa, Suvi
Hemminki, Otto
Kanerva, Anna
Santos, João M.
Cervera-Carrascon, Victor
Hemminki, Akseli
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 11 September 2024
Accepted: 26 October 2024
First Online: 6 November 2024
Declarations
:
: Informed consent was obtained from all patients prior to trial participation. TUNIMO – This study was approved by the Finnish National Committee on Medical Research Ethics (TUKIJA), approval number HUS/1804/2020. TUNINTIL—This study was approved by the Danish National Committee on Health Research Ethics (NVK); approval number 1905760. PROTA—This study was approved by the Finnish National Committee on Medical Research Ethics (TUKIJA); approval number TUKIJA/405/2021, and in the USA by FDA under the IND#027209.
: All patients enrolled into these studies gave informed consent for scientific publication.
: AH is shareholder in Circio Holdings ASA. AH, VCC, JHAC, JMS, CK, are employees and shareholders of TILT Biotherapeutics Ltd. OH is a shareholder of TILT Biotherapeutics. LH, DCAQ, SS are employees of TILT Biotherapeutics. MSB and IMS receive institutional research support from TILT Biotherapeutics. MSB serves as an advisory board member for TILT Biotherapeutics. Other authors declare no conflicts of interest.
